SAN DIEGO--(BUSINESS WIRE)--Lassen Therapeutics, a clinical stage biotech company developing first-in-class antibody therapeutics targeting interleukin-11 receptor (IL-11R) and interleukin-18 binding protein (IL-18BP) as potential treatments for fibro-inflammatory diseases, thyroid eye disease (TED) and for cancer, will present new preclinical and Phase I data of LASN01, a potential first-in-class IL-11 receptor (IL-11R) blocking antibody in development for treatment of pulmonary fibrosis, at the American Thoracic Society (ATS) Annual Meeting being held in Washington DC, May 19-24, 2023. In addition to the oral presentation at the Annual Meeting, Lassen has been invited to present at the ATS Respiratory Innovation Summit taking place on May 19, 2023. The summit brings together innovators, investors, clinicians, and advocacy groups who are leading the charge to create new treatments for deadly and crippling diseases of the lungs and airways.
The presentation at ATS will further provide data demonstrating the fibro-inflammatory role of IL-11 in the lung and other tissues, and includes clinical pharmacokinetic and pharmacodynamic data for LASN01. In the Phase I study, LASN01 exhibited dose-linear pharmacokinetics, with an excellent safety profile in healthy volunteers. Dose-dependent inhibition of receptor signaling was demonstrated in a blood-based assay, demonstrating potent activity of the circulating antibody. Data presented at last year’s ATS meeting showed that blockade of the IL-11 pathway with LASN01 inhibited STAT3 and ERK activation in human and mouse fibroblasts, and was anti-fibrotic in vitro, in vivo and in human ex vivo samples.
“We are pleased to be featured at ATS Respiratory Innovation Summit for an oral presentation describing the data for LASN01 and are excited to have been selected for the second year in a row as a featured company at the ATS Respiratory Innovation Summit,” said Maria Fardis, Ph.D., Chief Executive Officer of Lassen. “We believe that inhibition of signaling through IL-11R with LASN01 offers a potential novel treatment for idiopathic pulmonary fibrosis or other fibro-inflammatory diseases.”
Details of the Lassen presentation are as follows:
Title: A First-in-class IL-11 Receptor Blocking Antibody as a Treatment for Pulmonary Fibrosis
Mini-Symposium Session: New Perspectives on Translational Studies for Lung Fibrosis
Session Date and Time: Wednesday May 24, 2023, from 8:00 AM – 10:00 AM ET
About Lassen Therapeutics
Lassen Therapeutics is a clinical-stage biotech developing first-in-class antibodies as potential treatments for fibrosis, thyroid eye disease, and oncology. The company’s lead candidate, LASN01, is a first-in-class monoclonal antibody targeting IL-11 receptor (IL-11R). IL-11 is a central mediator of fibrosis and blocking its activity has the potential to offer novel modality for treatment of TED and other fibrotic diseases. For more information, please visit www.lassentherapeutics.com and follow us on LinkedIn.